SI4106757T1 - Postopki, ki vključujejo zaviralec nevtrofilne elastaze alvelestat, za zdravljenje bolezni dihal, ki jo sproži pomanjkanje antitripsina alfa-1 - Google Patents

Postopki, ki vključujejo zaviralec nevtrofilne elastaze alvelestat, za zdravljenje bolezni dihal, ki jo sproži pomanjkanje antitripsina alfa-1

Info

Publication number
SI4106757T1
SI4106757T1 SI202130071T SI202130071T SI4106757T1 SI 4106757 T1 SI4106757 T1 SI 4106757T1 SI 202130071 T SI202130071 T SI 202130071T SI 202130071 T SI202130071 T SI 202130071T SI 4106757 T1 SI4106757 T1 SI 4106757T1
Authority
SI
Slovenia
Prior art keywords
alvelestat
alpha
respiratory disease
methods involving
neutrophil elastase
Prior art date
Application number
SI202130071T
Other languages
English (en)
Inventor
Jacqueline Parkin
Original Assignee
Mereo Biopharma 4 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005519.0A external-priority patent/GB202005519D0/en
Priority claimed from GBGB2005520.8A external-priority patent/GB202005520D0/en
Application filed by Mereo Biopharma 4 Limited filed Critical Mereo Biopharma 4 Limited
Publication of SI4106757T1 publication Critical patent/SI4106757T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SI202130071T 2020-04-16 2021-03-16 Postopki, ki vključujejo zaviralec nevtrofilne elastaze alvelestat, za zdravljenje bolezni dihal, ki jo sproži pomanjkanje antitripsina alfa-1 SI4106757T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2005519.0A GB202005519D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
GBGB2005520.8A GB202005520D0 (en) 2020-04-16 2020-04-16 Elastase inhibition
US202062706195P 2020-08-04 2020-08-04
PCT/GB2021/050653 WO2021209739A1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
EP21714345.2A EP4106757B1 (en) 2020-04-16 2021-03-16 Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency

Publications (1)

Publication Number Publication Date
SI4106757T1 true SI4106757T1 (sl) 2023-11-30

Family

ID=78083570

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202130071T SI4106757T1 (sl) 2020-04-16 2021-03-16 Postopki, ki vključujejo zaviralec nevtrofilne elastaze alvelestat, za zdravljenje bolezni dihal, ki jo sproži pomanjkanje antitripsina alfa-1

Country Status (16)

Country Link
US (2) US20230218596A1 (sl)
EP (2) EP4252850A3 (sl)
JP (1) JP2023522010A (sl)
AU (1) AU2021256835A1 (sl)
DK (1) DK4106757T3 (sl)
ES (1) ES2962498T3 (sl)
FI (1) FI4106757T3 (sl)
HR (1) HRP20231065T1 (sl)
HU (1) HUE064089T2 (sl)
IL (1) IL297211A (sl)
LT (1) LT4106757T (sl)
MX (1) MX2022012942A (sl)
PL (1) PL4106757T3 (sl)
PT (1) PT4106757T (sl)
SI (1) SI4106757T1 (sl)
WO (2) WO2021209739A1 (sl)

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674708A (en) 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
ATE431364T1 (de) 1991-03-01 2009-05-15 Dyax Corp Inhibitoren der menschlichen elastase von neutrophilen
WO1992020357A1 (en) 1991-05-23 1992-11-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of cathepsin g and elastase for preventing connective tissue degradation
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
US5486529A (en) 1992-04-16 1996-01-23 Zeneca Limited Certain pyridyl ketones for treating diseases involving leukocyte elastase
US5441960A (en) 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
DE69314169T2 (de) 1992-04-16 1998-01-15 Zeneca Ltd Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
AU4077193A (en) 1992-04-16 1993-11-18 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
GB9307555D0 (en) 1992-04-16 1993-06-02 Zeneca Ltd Heterocyclic compounds
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
NZ284766A (en) 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
DE69531459T2 (de) 1994-06-02 2004-06-24 Aventis Pharmaceuticals Inc. Elatase-inhibitoren
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
GB9502152D0 (en) 1995-02-03 1995-03-29 Zeneca Ltd Proline derivatives
ATE261969T1 (de) 1996-03-28 2004-04-15 Glaxo Group Ltd Pyrrolopyrrolone als inhibitoren von neutrophiler elastase
US6103498A (en) 1996-04-12 2000-08-15 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
GB9719187D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd Compounds
JP2004517028A (ja) 1998-06-03 2004-06-10 コーテック インコーポレーテッド セリンプロテアーゼ阻害剤としてのα−ケトオキサジアゾール類含有インドールおよびテトラヒドロイソキノリン
JP2003520185A (ja) 1998-06-03 2003-07-02 コーテック インコーポレーテッド セリンプロテアーゼ阻害剤としてのα−ケトオキサジアゾール類
US20030069187A1 (en) 2001-10-05 2003-04-10 Rao Srinivasa K. Elastase inhibitors
US20030119073A1 (en) 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
TW200500341A (en) 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302323D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302324D0 (sv) 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
EP1730121B1 (en) 2004-02-26 2013-08-07 Bayer Intellectual Property GmbH 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
WO2006070012A1 (en) 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
TW200700392A (en) 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
PT2024367E (pt) 2006-05-04 2010-12-03 Pulmagen Therapeutics Inflammation Ltd Tetra-hidropirrolopirimidinadionas e a sua utilização a título de inibidores da elastase de neutrófilos humana
WO2009013444A1 (en) 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US7951823B2 (en) 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2019837B1 (en) 2006-05-23 2011-03-23 Irm Llc Compounds and compositions as channel activating protease inhibitors
ES2293832B1 (es) 2006-07-17 2009-05-04 Cargoflet S.A. Sistema de transporte masivo de gas natural a alta presion por via maritima.
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
NZ575907A (en) 2006-09-21 2011-03-31 Kyorin Seiyaku Kk 5-substituted benzoxazines
RS51644B (en) 2007-01-10 2011-10-31 Irm Llc. UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES
EP2117537A1 (en) 2007-02-09 2009-11-18 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009037413A1 (en) 2007-09-19 2009-03-26 Argenta Discovery Limited Dimers of 5- [ (4-cyanophenyl) sulfinyl] -6-methyl-2-oxo-1- [3- (trifluoromethyl)phenyl] -1,2-dihydropyridine-3-carboxamide as inhibitors of human neutrophil elastase for treating respiratory diseases
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
US8466284B2 (en) 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2009060206A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
GB0817429D0 (en) 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2483244A1 (en) 2009-10-02 2012-08-08 AstraZeneca AB 2-pyridone compounds used as inhibitors of neutrophil elastase
US20110212181A1 (en) 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
GB201004178D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
EP2766366B1 (en) 2011-09-14 2016-11-09 Chiesi Farmaceutici S.p.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhbitors
WO2013084199A1 (en) 2011-12-07 2013-06-13 Universidade De Lisboa Boron heterocycles as new inhibitors of human neutrophil elastase
BR112015000507A2 (pt) 2012-07-12 2017-06-27 Chiesi Farm Spa inibição de enzimas
US9102624B2 (en) 2012-08-23 2015-08-11 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057926A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
RU2016123379A (ru) 2013-12-16 2017-12-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Тетрагидротриазолопиримидиновые соединения в качестве ингибиторов нейтрофильной эластазы человека
WO2015096873A1 (en) 2013-12-27 2015-07-02 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
US10723765B2 (en) 2013-12-27 2020-07-28 Polyphor Ag Beta-hairpin peptidomimetics as selective elastase inhibitors
US9221807B2 (en) 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015200349A2 (en) * 2014-06-24 2015-12-30 The California Institute For Biomedical Research Elastase inhibitors
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EP3193910A1 (en) 2014-08-05 2017-07-26 Réunion Therapeutics B.V. Mutants of leech derived neutrophil elastase inhibitors and uses thereof
WO2016050835A2 (en) 2014-10-02 2016-04-07 Ruprecht-Karls-Universität Heidelberg Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
AR106958A1 (es) 2015-12-14 2018-03-07 Chiesi Farm Spa Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne
UA123109C2 (uk) 2016-05-31 2021-02-17 К'Єзі Фармачеутічі С.П.А. Сполуки імідазолону як інгібітори нейтрофіл-еластази людини
CN114650819A (zh) * 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
WO2021178448A1 (en) * 2020-03-02 2021-09-10 Motor Life Sciences, Llc Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity

Also Published As

Publication number Publication date
AU2021256835A1 (en) 2022-10-13
EP4106757A1 (en) 2022-12-28
ES2962498T3 (es) 2024-03-19
JP2023522010A (ja) 2023-05-26
EP4106757B1 (en) 2023-08-23
EP4252850A2 (en) 2023-10-04
IL297211A (en) 2022-12-01
MX2022012942A (es) 2023-01-11
US20230190723A1 (en) 2023-06-22
EP4252850A3 (en) 2023-11-15
FI4106757T3 (fi) 2023-10-23
HRP20231065T1 (hr) 2023-12-22
WO2021209740A1 (en) 2021-10-21
LT4106757T (lt) 2023-11-10
HUE064089T2 (hu) 2024-02-28
PL4106757T3 (pl) 2024-01-22
US20230218596A1 (en) 2023-07-13
DK4106757T3 (da) 2023-10-23
PT4106757T (pt) 2023-11-17
WO2021209739A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
WO2012145624A3 (en) Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
ZA200809024B (en) 2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
IL194843A0 (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
EP3980540A4 (en) METHOD FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
WO2008103277A3 (en) Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
DK2183268T3 (da) Fremgangsmåder til rensning af alpha-1-antitrypsin og apolipoprotein A-1
WO2008143633A3 (en) Compounds and methods for treatment of alpha-1 antitrypsin deficiency
IS7867A (is) 2-pýridónafleiður sem tálmar daufkyrningselastasa
TW200942527A (en) Pyridazine derivatives as factor XIa inhibitors
WO2017001936A3 (en) Therapeutic inhibitory compounds
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
IL267448A (en) Preparations and methods for treating alpha-1 antitrypsin deficiency
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
CY1117379T1 (el) Παραγωγα ιμιδαζολιου ως αναστολεις toy tafi-a
DK1590061T3 (da) Fremgangsmåde til rensning af alfa-1-antitrypsin
EP4106815A4 (en) METHODS OF TREATING ASTHMA OR ALLERGIES
PT4106757T (pt) Métodos que envolvem o inibidor da elastase neutrofílica alvelestat para o tratamento de doenças respiratórias mediadas pela deficiência de alfa 1 antitripsina
TW200716777A (en) Real-time monitoring and controlling sputter target erosion
MX2022002054A (es) Uso de un inhibidor de la elastasa de neutrofilo en la enfermedad pulmonar.
GB2592759B (en) New manufacturing process for 2-phase spray conditioner
EP3940384A4 (en) METHOD OF SCREENING A COMPOUND TO TREAT OR PREVENT POLYQ-RELATED NEURODEGENERATIVE DISEASES
IL193319A0 (en) Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases
GB202005519D0 (en) Elastase inhibition
ZA202208441B (en) Manufacturing method for high-strength cold-rolled pipe
EP4010337A4 (en) COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING NEURODEGENERATIVE DISEASES AND/OR ASSOCIATED CLINICAL CONDITION